Pfizer–BioNTech

E335285
pharmaceutical partnership strategic alliance

Pfizer–BioNTech is a pharmaceutical partnership best known for developing one of the first widely authorized mRNA vaccines against COVID-19.

Try in SPARQL Jump to: Surface forms Statements Referenced by

All labels observed (6)

Label Occurrences
Comirnaty 2
Pfizer–BioNTech COVID-19 vaccine 2
Pfizer and BioNTech SE 1

Statements (43)

Predicate Object
instanceOf pharmaceutical partnership ⓘ
strategic alliance ⓘ
clinicalTrialPhase3Sponsor BioNTech ⓘ
surface form: BioNTech SE

Pfizer ⓘ
developed BNT162b2 ⓘ
BNT162b2 ⓘ
surface form: Pfizer–BioNTech COVID‑19 vaccine
doseRegimen two‑dose primary series ⓘ
focusesOn COVID‑19 vaccine development ⓘ
infectious disease prevention ⓘ
geographicScope global ⓘ
hasBoosterFormulations true ⓘ
hasColdChainRequirement ultra‑low temperature storage ⓘ
hasManufacturingPartner Pfizer ⓘ
hasParticipant BioNTech ⓘ
surface form: BioNTech SE

Pfizer ⓘ
hasRegulatoryApprovalFor BNT162b2 ⓘ
surface form: Pfizer–BioNTech COVID‑19 vaccine
hasRegulatoryDesignation first mRNA vaccine to receive widespread authorization against COVID‑19 ⓘ
hasRegulatoryPathway Emergency Use Authorization ⓘ
full marketing authorization ⓘ
hasResearchPartner BioNTech ⓘ
surface form: BioNTech SE
hasVariantSpecificFormulations Omicron‑adapted COVID‑19 vaccine ⓘ
industry biotechnology industry ⓘ
pharmaceutical industry ⓘ
isCommercialCollaborationBetween Pfizer–BioNTech self-linksurface differs ⓘ
surface form: Pfizer and BioNTech SE
isFirstWidelyAuthorizedMRNAVaccineDeveloper true ⓘ
majorMarket Canada ⓘ
European Union ⓘ
Japan ⓘ
United Kingdom ⓘ
United States of America ⓘ
surface form: United States
notableWork BNT162b2 ⓘ
primaryIndication prevention of COVID‑19 ⓘ
productBrandName Comirnaty ⓘ
publicHealthImpact mass vaccination campaigns against COVID‑19 ⓘ
receivedEmergencyUseAuthorizationFor Pfizer–BioNTech self-linksurface differs ⓘ
surface form: Pfizer–BioNTech COVID‑19 vaccine
receivedEmergencyUseAuthorizationFrom European Medicines Agency ⓘ
Food and Drug Administration ⓘ
surface form: U.S. Food and Drug Administration

World Health Organization ⓘ
targetPathogen SARS-CoV-2 ⓘ
surface form: SARS‑CoV‑2
technologyUsed lipid nanoparticle delivery system ⓘ
messenger RNA ⓘ
usesPlatform BioNTech mRNA platform ⓘ
vaccineType mRNA vaccine ⓘ

Referenced by (8)

Full triples — surface form annotated when it differs from this entity's canonical label.

COVID-19 pandemic → majorVaccineDeveloper → Pfizer–BioNTech ⓘ
Pfizer → developed → Pfizer–BioNTech ⓘ
this entity surface form: Comirnaty
Pfizer → developed → Pfizer–BioNTech ⓘ
this entity surface form: Pfizer–BioNTech COVID-19 vaccine
Karikó → contributedTo → Pfizer–BioNTech ⓘ
subject surface form: Katalin Karikó
this entity surface form: Pfizer–BioNTech COVID-19 vaccine
BioNTech → developed → Pfizer–BioNTech ⓘ
this entity surface form: Comirnaty
BioNTech → partnerIn → Pfizer–BioNTech ⓘ
this entity surface form: Pfizer–BioNTech COVID-19 vaccine collaboration
Pfizer–BioNTech → receivedEmergencyUseAuthorizationFor → Pfizer–BioNTech self-linksurface differs ⓘ
this entity surface form: Pfizer–BioNTech COVID‑19 vaccine
Pfizer–BioNTech → isCommercialCollaborationBetween → Pfizer–BioNTech self-linksurface differs ⓘ
this entity surface form: Pfizer and BioNTech SE